Lutetium PSMA-617 | Clinical Trials Search

Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

3,426 results for “Lutetium PSMA-617”

Need more precision?

Filter by phase, recruitment status, country, sponsor, age, and study type.

Refine trial search

Lutetium-177-PSMA-617 in Low Volume Metastatic Prostate Cancer

10 participants · First posted Feb 4, 2019

Active, not recruiting

Lutetium-177-PSMA-617 in Oligo-metastatic Hormone Sensitive Prostate Cancer

58 participants · First posted Jun 23, 2020

Neoadjuvant Lu-PSMA Radioligand Therapy and Ipilimumab in Men With Very High-risk Prostate Cancer

1 participants · First posted Apr 29, 2024

A Study of 177Lu-PSMA-617 in People With Gliomas

20 participants · First posted Oct 31, 2025

177Lu-PSMA-617 and Pembrolizumab in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

43 participants · First posted Jan 15, 2019

Treatment of Patients With Progressive mCRPC With 177Lu-PSMA-617

30 participants · First posted May 15, 2025

Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer

30 participants · First posted Nov 9, 2021

Dose-Escalation Study of Cabozantinib in Combination With Lutetium-177 (177Lu)-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer

33 participants · First posted Nov 14, 2022

XL092 in Patients With Metastatic Castration-Resistant Prostate Cancer

32 participants · First posted Aug 23, 2024

Not yet recruiting

177Lu-PSMA, Niraparib/AA Plus Prednisone for Prostate Cancer

30 participants · First posted Mar 26, 2024

Page 1 of 206